European Commission approves faricimab for nAMD, DME

Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.

Ashvattha Therapeutics enrolls first patient in Phase 2 study of D-4517.2 for treatment of wet AMD, DME

The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.

Take-Home Points for the Treatment of AMD and DME

David A. Eichenbaum, MD, FASRS and Caroline Baumal, MD provide take-home messages to providers treating AMD and DME.